This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PULMINIQ

Novartis AG

Drug Names(s): CyIS, Aerosolized Cyclosporine

Description: PULMINIQ is an inhaled formulation of cyclosporine, an FDA-approved drug that has been part of the standard of care for heart, kidney and liver transplant patients for more than 20 years. Cyclosporine is a powerful immunosuppressant that has had a significant impact on transplant medicine. It inactivates T cells by inhibiting calcineurin phosphatase activity resulting in the inhibition of the transcription factor nuclear factor of activated T cells (NFAT).


PULMINIQ News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug